Drug intelligence / Profile preview

LZ-VZV-001

Development stage: Preclinical
Lead developer: Beijing Luzhu Biotechnology
Modality: Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
Administration: Intramuscular

Overview

LZ-VZV-001 is a recombinant protein vaccine candidate being developed by Beijing Luzhu Biotechnology (Green Bamboo Biopharmaceutical) for the prevention of varicella (chickenpox). The vaccine is designed to present varicella-zoster virus (VZV) antigens to the immune system to induce protective immunity. As a recombinant protein vaccine, it likely utilizes specific viral proteins, such as glycoprotein E (gE), rather than a live-attenuated virus, potentially offering a safer profile for certain populations. It is currently in the preclinical stage of development.

Other names: recombinant chickenpox vaccineLuzhu recombinant varicella vaccine

Targets

gE (VZV glycoprotein E)FcγR (Low affinity immunoglobulin gamma Fc region receptor II-c)

Beyond the preview

Go deeper on LZ-VZV-001.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on LZ-VZV-001.

Explore the full profile